{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7Z7p8LDA","lastupdate":"2023-03-01T00:00:00.000Z","update_date":"2023-03-01T00:00:00.000Z","lastModified":"Apr 25, 2025","active":1,"confidence_score":99,"confidence_score_reason":"video or image, markets","urlname":"anima-biotech","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$IIN6XFQ6umv6I0loiXZ6L3dFqfbFxhQO8iK0ZULdRN8SdUnwnxuWou","name":"Anima Biotech","oneliner":"Small-molecule mRNA Drug Discovery","registrar":"514460773","website":"https://www.animabiotech.com","careerspage":"","founded_month":6,"founded_year":2014,"formernames":["Anima Cell Metrology"],"sociallinks":{"twitter":"https://twitter.com/AnimaBiotech","youtube":"","facebook":"https://www.facebook.com/profile.php?id=100062978003577","linkedin":"https://www.linkedin.com/company/5385114","instagram":""},"social":["https://www.linkedin.com/company/5385114","https://twitter.com/AnimaBiotech","https://www.facebook.com/profile.php?id=100062978003577"],"flattenedsociallinks":"https://www.linkedin.com/company/5385114|https://twitter.com/AnimaBiotech|https://www.facebook.com/profile.php?id=100062978003577","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":62,"patent":1,"raised":30000000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["AnimaBiotech","Anima","ABI"],"about":"Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules.\n\nThis level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. \n\nAnima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators).\n\nIn addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972722148770","country":null,"address":{"israeli":[{"id":"77fbbc0f-0d8d-4119-bde5-6518ed996108","city":"Ramat Gan","type":null,"address":"Shoham St 2, Ramat Gan, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"1e13fe5a-9030-45c3-958f-64116567b182","city":"Bernardsville","address":"75 Claremont Road, Bernardsville, NJ, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"9WGfaKUFnMOudFVFlQ1O0JrVLogtnoRBUOyXujt0KjpIO0Iq9jaIO3","date":"Jan 17, 2023","link":"https://www.genengnews.com/topics/omics/rna/mrna/abbvie-to-develop-mrna-modulators-using-anima-biotech-platform/","source":"www.genengnews.com","visible":1,"analysis":{"tags":["mRNA biology modulators","collaboration","oncology","immunology","technology platform","mRNA Lightning","small molecules","partnerships","neurosciences","option fees","research and development milestones","commercial milestones","tiered royalties"],"company":"AbbVie","layoffs":null,"summary":"AbbVie has entered into a collaboration with Anima Biotech to discover and develop mRNA biology modulators for three targets in oncology and immunology. Animas mRNA Lightning platform will be used for this purpose. AbbVie will have exclusive rights to license, develop, and commercialize the programs. The collaboration combines AbbVies expertise in cancer and immunology drug development with Animas technology platform and expertise in mRNA biology. The collaboration includes an upfront payment of $42 million to Anima, with potential milestone payments and royalties on net sales. AbbVie also has the option to expand the collaboration with up to three additional targets. This collaboration is part of Animas strategy to form partnerships with biopharma giants, as it already has collaborations with Eli Lilly and Takeda Pharmaceutical.","partners":["Eli Lilly","Takeda Pharmaceutical"],"customers":null,"investors":null,"confidence":8,"key_topics":["mRNA biology modulators","collaboration","technology platform","small molecules","partnerships"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GtKhiLTEjotnj0XBWfLpCcVanwWPL6eFNEfTJS7KrfOz06ZAOetP2c","news_summary":"AbbVie to Develop mRNA Modulators Using Anima Biotech Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tvg7ld6CUPuGDfx3iiD9R6MiedKUyP6MqJWzm1nf2LfmfgXomWoQXa","date":"Jan 10, 2023","link":"https://news.abbvie.com/news/press-releases/abbvie-and-anima-biotech-announce-collaboration-for-discovery-and-development-mrna-biology-modulators-against-oncology-and-immunology-targets.htm","source":"news.abbvie.com","visible":1,"analysis":{"tags":"Partnership, Investment","company":"AbbVie and Anima Biotech","layoffs":"Not mentioned","summary":"AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs. Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales.","partners":"AbbVie","customers":"Not mentioned","investors":"AbbVie","confidence":9,"key_topics":"Collaboration, mRNA Lightning technology, Oncology, Immunology, Investment","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$42 million upfront, up to $540 million in potential milestones","structured_issues":"Partners, Investment","acquisition_amount":"Not applicable","structuredIssuesShow":"#Partners, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QkZAz20WOyCfpDCkGpviSN1svEzHAdakaYwqeeZaurIPaIJtVm4t4I","news_summary":"AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sZbSqDqcoeBhz6XCap2s6rB4JHAtHEMcq3ynnm78E3RDdJhRguFE1f","date":"Dec 14, 2022","link":"https://www.globenewswire.com/en/news-release/2022/12/14/2573869/0/en/Anima-Biotech-To-Present-And-Participate-In-Panel-Discussion-At-The-5th-RNA-Targeted-Drug-Discovery-Summit.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"panel discussion, presentation, RNA Targeted Drug Discovery Summit","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will participate in a panel discussion and give a presentation at Hanson Wades 5th RNA Targeted Drug Discovery Summit. The companys chief business officer will join the Biopharma & Investment Partnerships panel and give a presentation on the mRNA Lightning Platform. Anima Biotech is a leader in the discovery of small molecule mRNA drugs and their mechanisms of action. They use phenotypic screening with AI-driven MOA elucidation. The company has a broad pipeline across 18 different discovery programs in various therapeutic areas, including Fibrosis, Oncology, and Neuroscience. They have also established strategic collaborations with pharmaceutical companies such as Lilly and Takeda Pharmaceuticals.","partners":"Lilly, Takeda Pharmaceuticals","customers":null,"investors":null,"confidence":9,"key_topics":["mRNA drugs","phenotypic screening","AI","RNA investment","collaborations"],"date_of_event":"December 13, 2022 to December 15, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9NDaWb1DCIK6Clvfu1fjHujab7uOqMKt1Z4xFss41y09Dl1dswdCbz","news_summary":"Anima Biotech To Present And Participate In Panel Discussion At The 5th RNA Targeted Drug Discovery Summit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jl6HFfgh1pyX1gi0h9ebdMkkOPHI1URIWkUQfaYsNN3MUNn1IOBHDV","date":"Jul 20, 2022","link":"https://www.globenewswire.com/en/news-release/2022/07/20/2482708/0/en/Anima-Biotech-Achieves-Milestone-in-Takeda-Collaboration.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"collaboration","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech has achieved a milestone in its collaboration with Takeda, entitling them to an undisclosed milestone payment. The collaboration, initiated in March 2021, aims to discover and develop a new class of medicines for genetically-defined neurological diseases. Anima Biotech used its mRNA Lightning platform to discover novel mRNA translation modulators against the collaboration targets. The milestone achievement demonstrates the advantage of Animas approach with small molecule mRNA drugs. Anima Biotech has a broad pipeline across 18 different discovery programs in various therapeutic areas and has established strategic collaborations with pharmaceutical companies, including Takeda.","partners":["Takeda"],"customers":null,"investors":null,"confidence":8,"key_topics":["milestone","collaboration","small molecule mRNA drugs","Takeda","neurological diseases"],"date_of_event":"2022-07-20","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"owPwl7wjFdGSzx15a5IdTXzJDUCvKJ0y80eTvCYP8U4L4Yl6MwGASU","news_summary":"Anima Biotech Achieves Milestone in Takeda Collaboration","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xGCY6UeWS3HP07Pa9y2paJAqK17CerrupQxRyMiqCs0tubAVLJbR2E","date":"Apr 19, 2022","link":"https://finance.yahoo.com/news/anima-biotech-present-3rd-annual-141700461.html?guccounter1&guce_referreraHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sigAQAAADDvJ_9NctqpSsvyU-RHV_7AV8TWVPPs7XEe9jVdLbxvXyc5OpCEzAqOXgIdAtHrsvNb7HkFyw5dh8IXeGASEePSGYm_2w8OvkjpjEsSpY95zbXl-aqfkZwfxFI5OvS8PuxBHhV-okbCEWDEv42WIvDqfOxNgVvuQhLlSlqBWJvp","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"presentation","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will be presenting at a conference on RNA-Targeting Small Molecule Drugs. The companys Co-Founder and Chief Scientific Officer will give a presentation on their mRNA Lightning Platform. Anima Biotech is advancing the platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. They have a broad pipeline across various therapeutic areas and strategic collaborations with pharmaceutical companies. The companys science has been validated with patents, publications, and scientific collaborations.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["mRNA drugs","RNA-Targeting Small Molecule Drugs","AI image analysis","platform","therapeutic intervention"],"date_of_event":"April 20, 2022 to April 21, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IzeAIUYTiZs5NBYJvgdbMY24IElJxqdxofaZecqwFwuhXuh28swQ7f","news_summary":"Anima Biotech to Present at the 3rd Annual RNA-Targeting Small Molecule Drugs Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wpYYBW6hAtjVsKswTsNCIxCPN8BVKVCqA90XaPeFIzYbmd7gwwwRPw","date":"Oct 12, 2021","link":"https://www.globenewswire.com/en/news-release/2021/10/12/2312782/0/en/Anima-Biotech-to-Present-at-Multiple-RNA-Related-Scientific-Conferences-in-October.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"RNA, small molecule mRNA drugs","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will be presenting at two conferences, Society of Chemical Industry (SCI)s RNA as a Target For The Life Sciences and Elrigs Drug Discovery 2021. The companys Vice President of Research and Development, Iris Alroy, will give presentations on mRNA translation modulators and the mRNA Lightning platform. Anima Biotech is a leader in the discovery of selective small molecule mRNA drugs and their mechanisms of action. They have a broad pipeline across various therapeutic areas and strategic collaborations with pharmaceutical companies. The company has patents, publications, and scientific collaborations that validate their science.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["RNA as a Target For The Life Sciences","mRNA translation modulators","mRNA Lightning platform","Selective small molecule mRNA drugs","Strategic collaborations"],"date_of_event":"October 12-13, 2021 and October 19-20, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iDclys7RuUC6Ca5ERyguMCh0eJPrhmIPG4pbXypLUyeBmU3hGGudYR","news_summary":"Anima Biotech to Present at Multiple RNA-Related Scientific Conferences in October","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2cjADCWfedDc9izkzFs1qD000H6Kp127czG0NntVCoqlcGY4M5Exrj","date":"Mar 18, 2021","link":"https://www.globenewswire.com/news-release/2021/03/18/2195616/0/en/Anima-Biotech-Announces-Strategic-Collaboration-with-Takeda-to-Discover-and-Develop-mRNA-Translation-Modulators-for-Neurological-Diseases.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"strategic collaboration","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited to discover and develop a new class of medicines for genetically-defined neurological diseases. Takeda will pay Anima up to approximately $120 million in upfront and preclinical research milestone payments and up to $1.1 billion in clinical and commercial milestones, assuming success of the three programs. Anima is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Takeda has a time-limited option to expand the collaboration with up to three additional targets subject to additional payments to Anima of up to $1.2 billion and tiered royalties, assuming success of these programs.","partners":["Takeda Pharmaceutical Company Limited"],"customers":null,"investors":null,"confidence":9,"key_topics":["strategic collaboration","mRNA translation modulators","genetically-defined neurological diseases","Huntingtons Disease program","upfront and milestone payments"],"date_of_event":"March 18, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vrZBu2Fsnzv79fqmnaOmf8ousugQvpXqzebcojyPWzBJSs1gRNHNx9","news_summary":"Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fb3729ba-3b03-45a2-93dc-b8f198aa1f4b","date":"Sep 4, 2019","link":"https://www.globenewswire.com/news-release/2019/09/04/1910952/0/en/Anima-Biotech-to-Present-at-the-12th-Annual-BioPharm-America-International-Partnering-Conference.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"presentation, partnering, translation control therapeutics","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will present at the 12th Annual BioPharm America International Partnering Conference. The companys Vice President of Business Development will discuss their Translation Control Therapeutics technology for the discovery of small molecule drugs that specifically control mRNA translation. Anima Biotechs approach targets proteins that regulate translation, leading to a novel target space. They have a pipeline of drug candidates and collaborate with pharmaceutical companies, including a $1B+ collaboration with Lilly. The company has 5 granted patents, 14 peer-reviewed publications, and 17 scientific collaborations. Anima Biotech is focused on advancing Translation Control Therapeutics as a new strategy against various diseases.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["BioPharm America International Partnering Conference","Translation Control Therapeutics","mRNA translation","small molecule drugs","target proteins"],"date_of_event":"September 11, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cE4KBLHJvEpztPeDy16yU0x85Ox2V2dtKOcuHcGg3Mad22FvhC7p6X","news_summary":"Anima Biotech to Present at the 12th Annual BioPharm America International Partnering Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"05583409-18cb-4221-8d89-f117231c67f8","date":"May 31, 2019","link":"https://www.globenewswire.com/news-release/2019/05/31/1861189/0/en/Anima-Biotech-to-Present-at-the-2019-BIO-International-Convention.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"presentation, partnering activities","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will present at the 2019 BIO International Convention and provide an overview of the companys business, technology, and partnering activities. The CEO will participate in a CEO breakfast panel. Anima Biotech is advancing Translation Control Therapeutics, a platform for the discovery of small molecule drugs that specifically control mRNA translation. They have a pipeline across therapeutic areas and a partnership with Lilly for the discovery and development of translation inhibitors. The company has 5 granted patents, 14 peer-reviewed publications, and 17 scientific collaborations.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["BIO International Convention","Translation Control Therapeutics","mRNA translation","small molecule drugs","pipeline"],"date_of_event":"2019-06-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JChNS9GnI25soa4GELVIVSEkMkw4QIYyAvdUsk84GXoUTfxFgs4mkf","news_summary":"Anima Biotech to Present at the 2019 BIO International Convention","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bc4468ee-1e74-4048-9db1-4e334162b63f","date":"May 28, 2019","link":"https://www.pharmasalmanac.com/articles/what-truly-novel-therapies-in-the-earliest-stages-of-discovery-and-development-do-you-believe-will-have-a-significant-impact-in-the-future","source":"www.pharmasalmanac.com","visible":1,"analysis":{"tags":"Novel Therapies","company":"Anima Biotech","summary":"The article discusses various novel therapies in the pharmaceutical industry, including the use of mRNA, biologics, gene therapy, RNA editing, and antisense oligonucleotides. Anima Biotechs Translation Control Therapeutics is highlighted as a platform for the discovery of small molecule drugs that control the translation of mRNA. The impact on the company is growth-positive, as it offers a novel strategy for drug discovery. The key issues discussed in the article are drug development and drug discovery. The date of the event described in the article is not provided. The confidence level of the answer is 8.","investors":null,"key_topics":["mRNA","biologics","gene therapy","RNA editing","antisense oligonucleotides"],"impact_on_company":"growth-positive","structured_issues":["Drug Development","Drug Discovery"],"structuredIssuesShow":"#Drug Development  #Drug Discovery","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xlYoAXwgABRTdufVW55QRN3dXZFiyYN0eMXgLRbdKlLxH4UB8cqwVp","news_summary":"Q: What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"10cf7d5f-b9be-4e52-a1cc-d0db5e35746e","date":"May 24, 2019","link":"https://www.biocentury.com/bc-innovations/emerging-company-profile/2019-05-23/how-anima-leveraging-its-translational-control-","source":"www.biocentury.com","visible":1,"analysis":{"tags":"translational control platform, small molecules, big pharma deals","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech is leveraging its translational control platform to pursue new targets, small molecules, and big pharma deals. Their strategy of targeting the machinery that turns mRNA into protein gives them an advantage over competitors. Anima Biotech was launched in 2014 with technology from the University of Pennsylvania that allows them to visualize protein translation and track the impact of different molecules on the process.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["undruggable targets","gene regulation","mRNA","protein expression","technology"],"date_of_event":"May 24, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jZxVeaMAGkwImhZT1Iw7bAcwbaYsbmub66X7hUJsjRKgjtltEStafX","news_summary":"Anima opens new target space in translational control","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"69bdba28-c077-454a-a068-ccef393025e5","date":"May 22, 2019","link":"https://www.biospace.com/article/mrna-and-artificial-intelligence-an-interview-with-animabiotech-s-yochi-slonim/","source":"www.biospace.com","visible":1,"analysis":{"tags":["mRNA therapeutics","AI","drug development","ribosomes","protein production"],"company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech, a biopharma company, is merging mRNA therapeutics with AI and bioinformatics. Their unique approach involves discovering molecules that control the translation of mRNA by ribosomes into protein. The companys technology allows them to visualize protein production in real-time using imaging techniques and an AI system. Anima Biotech has a major partnership deal with Eli Lilly, although specific targets and diseases are not disclosed. The AI system analyzes billions of data points to identify compounds that interact with ribosomes and increase or decrease protein production. The combination of biological understanding and AI software gives Anima Biotech an edge in the field of AI applied to drug discovery. The company aims to be in the clinic within 18 months to two years.","partners":["Eli Lilly"],"customers":null,"investors":"Eli Lilly","confidence":8,"key_topics":["mRNA therapeutics","AI","ribosomes","protein production","partnership"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oMHQSbNgSrdsEFG1Y3HQRMupYB1dBsxtOjDv6srgkaMGDAl1iyvxyC","news_summary":"mRNA and Artificial Intelligence: An Interview with Anima Biotech's Yochi Slonim  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ac537901-e193-4161-8469-adfbacde20be","date":"May 6, 2019","link":"https://www.globenewswire.com/news-release/2019/05/06/1817595/0/en/Anima-Biotech-to-Present-at-the-11th-Annual-International-ChinaBio-Partnering-Forum-2019.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"business development","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will present at the 11th Annual International ChinaBio Partnering Forum 2019 in Shanghai, China. The companys vice president of business development will provide an overview of Anima Biotechs business, technology, and partnering activities. Anima Biotech is focused on the discovery of small molecule drugs that control mRNA translation as a new strategy against diseases. They have a pipeline of drug candidates and collaborate with pharmaceutical companies, including a $1 billion collaboration with Lilly. The company has received patents, published scientific articles, and engaged in scientific collaborations. For more information, visit their website.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["ChinaBio Partnering Forum","Translation Control Therapeutics","mRNA translation","small molecule drugs","pharmaceutical collaborations"],"date_of_event":"May 8, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ccCAOvhpYOPfWKluMTMtsqxDzS9uNUyigKL6OExwFU1b6PdUSDbVgX","news_summary":"Anima Biotech to Present at the 11th Annual International ChinaBio Partnering Forum 2019","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"55f2c8a1-87a0-41aa-a1d2-60542ffbfb1f","date":"Feb 28, 2019","link":"https://www.globenewswire.com/news-release/2019/02/28/1744459/0/en/Anima-Biotech-to-Present-at-the-Annual-2019-BIO-Asia-International-Conference.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"business development","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech will present at the Annual 2019 BIO Asia International Conference in Tokyo, Japan. The companys Vice President of Business Development will provide an overview of the companys business, technology, and partnering activities. Anima Biotech is advancing Translation Control Therapeutics, a platform for the discovery of small molecule drugs that specifically control mRNA translation. They have a partnership with Lilly for the discovery and development of translation inhibitors. The company has 5 granted patents, 14 peer-reviewed publications, and 17 scientific collaborations.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["BIO Asia International Conference","Translation Control Therapeutics","mRNA translation","small molecule drugs","Pharma partnership"],"date_of_event":"March 5, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"g5XFi72o6AsrqxFEDePhFkN473OEDzCvGDt5lkplFtsklyTZ240qBf","news_summary":"Anima Biotech to Present at the Annual 2019 BIO Asia International Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"66d01f24-1934-4476-a9a5-699d46b2ff61","date":"Nov 15, 2018","link":"https://www.animabiotech.com/video/eli-lilly-co-and-anima-biotech-win-us-deal-year-lifestars-awards-2018","source":"www.animabiotech.com","visible":1,"analysis":{"tags":"collaboration, drug discovery","company":"Eli Lilly & Co.","layoffs":null,"summary":"The article discusses the collaboration between Eli Lilly & Co. and Anima Biotech, highlighting the potential of Animas Translation Control Therapeutics technology in the future of drug discovery at Eli Lilly.","partners":["Anima Biotech"],"customers":null,"investors":null,"confidence":8,"key_topics":["Collaboration","Translation Control Therapeutics","Drug discovery"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ACHrdc8I2FbEVc1T0cPWZNX7ns499ONu2o2Vl3qrNpVKxkKUYnqzcQ","news_summary":"Eli Lilly & AnimaBiotech win US Deal of the Year Award","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9b455e6c-325c-4b9f-82cf-8331a278a408","date":"Aug 1, 2018","link":"https://pharmaintelligence.informa.com/resources/product-content/anima-biotech-lighting-the-way-in-protein-translation","source":"pharmaintelligence.informa.com","visible":1,"analysis":{"tags":"protein translation","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech, a pioneer in translation control therapeutics, has partnered with Eli Lilly for the discovery and development of translation inhibitors for several target proteins. Animas technology controls protein translation by causing ribosomes to emit light pulses, allowing for real-time visualization and monitoring of protein production. The company is running programs in fibrosis, respiratory syncytial virus, oncology, and neuroscience. Anima has raised over $30 million in private investment and will receive $30 million in upfront payments and $14 million in research funding from the partnership with Eli Lilly. The company is focused on growing its pipeline and forming more partnerships in the pharmaceutical industry.","partners":"Eli Lilly","customers":null,"investors":"Eli Lilly","confidence":8,"key_topics":["protein translation","translation control therapeutics","ribosomes","partnership strategy","pipeline opportunities"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HeI1NfEHzZljBlKENCY3O8PUUebWgDCDIrAcXWQTcST4O5BPH9Fx0d","news_summary":"Anima Biotech: Leading Protein Translation l Pharma Intelligence","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"04380865-51a5-49bd-9fcf-bb3e86410d7c","date":"Jul 23, 2018","link":"https://www.prnewswire.com/news-releases/anima-biotech-announces-an-exclusive-collaboration-with-lilly-for-the-discovery-and-development-of-translation-inhibitors-of-several-protein-targets-876239046.html","source":"www.prnewswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"nwHLYHfC1YN9PhdRGp6IQqseMamTwlTTx0DlQ8lCvMI5DKFaLFbnkx","news_summary":"Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"38772ece-c859-4d66-b9a1-deb47e1be353","date":"Apr 13, 2018","link":"https://labiotech.eu/biotech-of-the-week/anima-biotech-protein-translation/","source":"labiotech.eu","visible":1,"analysis":{"tags":"drug development","company":"Anima Biotech","layoffs":null,"summary":"Anima Biotech, an Israeli company, is developing a new class of drugs that target protein translation to combat diseases. Their Protein Synthesis Monitoring Technology tracks protein synthesis in real time and uses machine learning analysis to identify molecules that could treat fibrosis, viral infections, lung cancer, and Huntingtons disease. The company has formed partnerships with international collaborators in academia and industry. However, their drug candidates have not yet entered preclinical testing.","partners":"Duke University, University of Oxford","customers":null,"investors":null,"confidence":8,"key_topics":["Anima Biotech","protein translation","disease","drug development","technology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WJh1xWVijSZm9KREfCtISuvEzOJ4y2vMZtM5y84o9hTpgJFyTIxm91","news_summary":"This Israeli Biotech Targets Protein Translation to Fight Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":18,"techcommunityinvolvement":null,"mediagallery":[],"tags":["immunology","drug-discovery","biotechnology","neurology","cancer","biopharmaceutical","proteins","pharmaceuticals","artificial-intelligence","oncology","neuroscience","pharma-companies","patent-pending"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":[],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$30M","totalrounds":1,"fundingstage":"Seed","totalfunding":"$30M","publicinvestors":1,"lastpublicfunding":30000000,"totalpublicrounds":1,"totalpublicfunding":30000000},"team":[{"name":"Yochi Slonim, M.Sc.","email":"yochi@ffwd.me","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLGrsOEIDA","bounced":true,"claimed":1,"founder":1,"urlname":"yochi-slonim-msc","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAnunjpAkM","position":"Co-Founder & CEO","last_name":"Slonim, M.Sc.","claimtoken":"ff3d469536e2e495f9f95f72450da3a144d7e622b23e1e6db19bea1e1777e61f","first_name":"Yochi","picturekey":"$CkI3JoSOmbAsEj3eRmEqcCYcQUWgByxOXd4hFG7TrPqsUG3bdRJkQw","claimeddate":"2015-02-12","linkedinurl":"https://www.linkedin.com/in/yochislonim","unsubscribed":false,"is_activeuser":0,"additionalemail":"yochi.slonim@animabiotech.com","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$CkI3JoSOmbAsEj3eRmEqcCYcQUWgByxOXd4hFG7TrPqsUG3bdRJkQw","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Zeev Smilanski, Ph.D.","email":"zeev.smilanski@animabiotech.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGyirQJDA","bounced":true,"claimed":0,"founder":1,"urlname":"zeev-smilanski-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAvo6nrAoM","position":"Co-Founder & CTO","last_name":"Smilanski, Ph.D.","claimtoken":"XWadmqHmk6YA9JcY9MpyO69zFelfzUDld1t1BaBf748oSuHXpezLN5","first_name":"Zeev","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/zeev-smilansky-2a7883/","unsubscribed":true,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-03-01 13:42:47.000000","initials":"ZS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Iris  Alroy","email":"iris.alroy@animabiotech.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgJ7q3ZsJDA","bounced":false,"claimed":0,"founder":0,"urlname":"iris-alroy","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAvtqZiwgM","position":"Co-founder & CSO","last_name":"Alroy","claimtoken":"G2vMcBLelcCZVUdZsYU2tPh5or10vwdCiCbEObVMI8KNGXJlj0HNIP","first_name":"Iris ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/iris-alroy-5254947/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-03-01 13:43:18.000000","initials":"IA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Avi Eliassaf","email":"avi.eliassaf@animabiotech.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNXE5YQLDA","bounced":false,"claimed":0,"founder":0,"urlname":"avi-eliassaf","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgxdHE6wsM","position":"COO","last_name":"Eliassaf","claimtoken":"j0UHWUjZkQ3AeIzv1g8aUJ8Qcrw5xwpZQxHV77ZYGHpIReEdfpyFzW","first_name":"Avi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/avi-eliassaf-23944/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-03-01 13:45:09.000000","initials":"AE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yossi Oulu","email":"yossi.oulu@animabiotech.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJWtwsoJDA","bounced":false,"claimed":0,"founder":0,"urlname":"yossi-oulu","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgtZrfnwsM","position":"VP Digital Tecgnologies","last_name":"Oulu","claimtoken":"tnpzUzGxDnwDeTJeuJM6ZC1uYPoQjDaql9rp9ErHOM8pUYLszmIzM6","first_name":"Yossi","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-03-01 13:46:06.000000","initials":"YO","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-05-18T00:00:00.000Z","crunchbaseid":"anima-biotech","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yanina Wainscheinker","creator_email":"yanina.wain@gmail.com","createdate":"2015-02-12T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2q-UCww","date":"Jan 2018","amount":"$30M","source":"Added by Clara Assouline","eventtype":"FundingRoundEvent","investment":[{"name":" National Institute of Health (NIH)","type":"Investor","amount":null,"hidden":false,"country":"US","fullurl":"/investor_page/national-institute-of-health-nih","logokey":null,"tagline":"","urlname":"/investor_page/national-institute-of-health-nih","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIHgCAw","fundingtype":"Grant Provider","leadpartner":null,"investmentid":"pIYnWyMijlXJaZrxIiLtqu4O0RGn6VPwWFj3w7C166ozTINWvUh1tA","fundingsubtype":"Grant Provider","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2014","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Anima Biotech","logourl":"https://storage.googleapis.com/clean-finder-353810/$IIN6XFQ6umv6I0loiXZ6L3dFqfbFxhQO8iK0ZULdRN8SdUnwnxuWou","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$IIN6XFQ6umv6I0loiXZ6L3dFqfbFxhQO8iK0ZULdRN8SdUnwnxuWou","seoabout":"Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The co...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Platforms & Interfaces","key":"0-0","path":"TechnologyClassificationModel>Platforms & Interfaces","children":[{"title":"Software","key":"0-0-0","path":"TechnologyClassificationModel>Platforms & Interfaces>Software"}]},{"title":"Biologicals","key":"0-1","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-1-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]},{"title":"Artificial Intelligence","key":"0-2","path":"TechnologyClassificationModel>Artificial Intelligence"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Platforms & Interfaces","Software","Biologicals","Molecules","Artificial Intelligence"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2q-UCww","date":"Jan 2018","amount":"$30M","source":"Added by Clara Assouline","eventtype":"FundingRoundEvent","investment":[{"name":" National Institute of Health (NIH)","type":"Investor","amount":null,"hidden":false,"country":"US","fullurl":"/investor_page/national-institute-of-health-nih","logokey":null,"tagline":"","urlname":"/investor_page/national-institute-of-health-nih","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIHgCAw","fundingtype":"Grant Provider","leadpartner":null,"investmentid":"pIYnWyMijlXJaZrxIiLtqu4O0RGn6VPwWFj3w7C166ozTINWvUh1tA","fundingsubtype":"Grant Provider","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}